U.S. Life Sciences Stock News

NYSE:RPC
NYSE:RPCCapital Markets

Ridgepost Capital (RPC) Valuation Check After Rebrand And High P/E Versus Peers

Why Ridgepost Capital Is On Investors’ Radar Ridgepost Capital (RPC) recently rebranded from P10, Inc. This shift is putting fresh attention on how this multi asset class private market solutions provider is positioned across private equity, venture capital, impact investing, and private credit. See our latest analysis for Ridgepost Capital. At a latest share price of $8.70, Ridgepost Capital has seen a 2.35% 1 day share price return. Its 30 day share price return of 18.77% and 1 year total...
NYSE:AKR
NYSE:AKRRetail REITs

Acadia Realty Trust (AKR) FFO Stability Reinforces Bullish Urban Retail Narratives

Acadia Realty Trust (AKR) has wrapped up FY 2025 with fourth quarter revenue of US$106.7 million and basic EPS of US$0.04, alongside funds from operations of US$41.6 million, which is a key earnings gauge for REIT investors. The company has seen quarterly revenue move from US$92.8 million in Q4 2024 to US$106.7 million in Q4 2025, while basic EPS shifted from US$0.07 to US$0.04 over the same period. Investors may now weigh the solid top line momentum against margins that are likely to be...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance

NeoGenomics, NasdaqCM:NEO, has launched PanTracer Pro, a new diagnostic solution for clinicians treating advanced stage solid tumors. The offering combines broad genomic profiling and customized diagnostic testing into a single order with a focus on faster turnaround times. PanTracer Pro is designed to address fragmented testing workflows, treatment delays, and incomplete biomarker assessment in cancer care. NeoGenomics, trading at $11.38, has seen mixed share price performance, with a 30...
NYSE:NSC
NYSE:NSCTransportation

Norfolk Southern Union Pacific Merger Reshapes Rail Network And Risk Profile

Norfolk Southern (NYSE:NSC) has entered into a merger agreement with Union Pacific to form what is described as America's first transcontinental railroad. The transaction comes while Norfolk Southern continues to face legal proceedings related to the 2023 East Palestine incident. These developments are expected to affect the company's operations, regulatory profile, and position within the North American rail industry. For investors watching Norfolk Southern at a share price of $314.94,...
NYSE:MH
NYSE:MHConsumer Services

Is McGraw Hill (MH) Pricing Reflect Its Recent Share Price Weakness And Cash Flow Outlook

If you are asking yourself whether McGraw Hill is priced attractively right now, this article will walk through what the current share price might be implying about the business. The stock last closed at US$13.67, with a recent 7 day return of 8.3%, a 30 day return of 5.7% decline, and a year to date return of 16.4% decline, which may have caught your eye if you are watching for changing risk and reward. Recent evergreen coverage interest around McGraw Hill has focused on how the market is...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences (EXAS) Loss Rebound In Q4 Challenges Profitability Progress Narrative

Exact Sciences (EXAS) just reported its FY 2025 numbers with fourth quarter revenue of US$878.4 million, a basic EPS loss of US$0.45 and net income loss of US$86.0 million, while on a trailing twelve month basis revenue came in at about US$3.2 billion with a basic EPS loss of US$1.10 and a net income loss of US$207.9 million. The company has seen quarterly revenue move from US$713.4 million in Q4 2024 to US$878.4 million in Q4 2025, with basic EPS losses over that span ranging from US$4.67 to...
NasdaqGS:SBRA
NasdaqGS:SBRAHealth Care REITs

Sabra Health Care REIT Shifts CIO As Senior Housing Growth Accelerates

Sabra Health Care REIT (NasdaqGS:SBRA) has appointed Darrin Smith as Chief Investment Officer, Secretary, and Executive Vice President following the retirement of Talya Nevo-Hacohen. The company reports strong operational execution, with gains in occupancy, NOI, and margin within its senior housing portfolio. Sabra highlights an investment pipeline for 2026 that it expects to exceed already high 2025 levels. Sabra Health Care REIT, trading at around $20.17, enters this management transition...
NYSE:PHIN
NYSE:PHINAuto Components

PHINIA Growth Story Links 2025 Execution With 2026 Transition Goals

PHINIA Inc. (NYSE:PHIN) reported year over year growth across key business segments in 2025. The company recorded three consecutive quarters of growth in both Fuel Systems and Aftermarket segments. Management reduced debt, improved leverage, and expressed optimism for 2026. Leadership is targeting further market share gains in areas such as Gasoline Direct Injection and alternative fuels. PHINIA, trading as NYSE:PHIN, focuses on Fuel Systems and Aftermarket products that support internal...
NasdaqCM:FONR
NasdaqCM:FONRMedical Equipment

Fonar (FONR) Margin Compression To 6.7% Reinforces Profitability Concerns After Q2 2026 Results

FONAR (FONR) has just posted its Q2 2026 numbers, with quarterly revenue of about US$26 million and basic EPS of US$0.33, setting the stage against a year of trailing EPS of roughly US$1.08 on revenue of about US$105 million. Over recent quarters, the company has seen revenue move between roughly US$24.9 million and US$27.3 million, while quarterly EPS has ranged from about US$0.11 to US$0.46. This has left investors focused on how these latest figures feed into a story of compressing margins...
NYSE:NABL
NYSE:NABLSoftware

Assessing N-able (NABL) Valuation After Recent Share Price Weakness And Fair Value Gap

Why N-able (NABL) is on investors’ radar N-able (NABL) has drawn investor attention after recent trading left the stock at US$5.35, with returns over the past month and past 3 months under pressure and the 1 year total return also negative. With annual revenue of US$497.665 million and net income reported as a US$6.511 million loss, the company’s value score of 6 and an indicated intrinsic discount provide a starting point for investors assessing risk and potential reward. See our latest...
NasdaqCM:NEOV
NasdaqCM:NEOVElectrical

NeoVolta (NEOV) Revenue Surge To US$6.7 Million Tests High P/S Market Narrative

NeoVolta (NEOV) has just posted its Q2 2026 numbers, with Q1 2026 revenue at US$6.7 million and a net loss of US$1.2 million, translating into basic EPS of a US$0.04 loss. The company has seen quarterly revenue move from US$0.6 million in Q1 2025 through US$1.1 million in Q2 2025, US$2.0 million in Q3 2025 and US$4.8 million in Q4 2025 to US$6.7 million in Q1 2026, while EPS over the same stretch ranged from a loss of US$0.03 to a loss of US$0.05 per share. For investors, the latest set of...
NYSE:TPR
NYSE:TPRLuxury

Tapestry’s Direct Approach And Gen Z Gains Support Upgraded Growth Outlook

Tapestry (NYSE:TPR) reported strong quarterly results, highlighting global customer acquisition and growing Gen Z engagement. Management pointed to increased effectiveness of its direct to consumer approach, marketing efforts, and product development. The company raised its full year revenue outlook, citing higher operating margins and improved profitability. Tapestry, the owner of several luxury and premium brands, is drawing attention after this update, especially given its recent share...
NasdaqGS:TPG
NasdaqGS:TPGCapital Markets

Is It Time To Reassess TPG (TPG) After A 26% One Month Share Price Slide

If you are wondering whether TPG’s share price reflects its underlying worth right now, you are not alone. This article is here to frame the key valuation questions you might be asking. After reaching a recent close of US$49.53, the stock has seen a 10% decline over the last 7 days and a 26.2% decline over the last 30 days, while still showing a 64.5% return over 3 years and mixed results over shorter periods including year to date and the last 12 months. Recent news coverage around TPG has...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant mCRC Regimen

On February 4, 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, microsatellite-stable metastatic colorectal cancer. The designation is backed by clinical data showing pelareorep-based therapy delivered higher response rates and longer survival measures than existing standard-of-care options in this hard-to-treat subgroup. With the FDA’s Fast Track Designation in place,...
NYSE:HCC
NYSE:HCCMetals and Mining

Warrior Met Coal Ramps Up Blue Creek As Earnings Story Shifts

Warrior Met Coal (NYSE:HCC) has started longwall production at its Blue Creek mine around eight months ahead of its original schedule. The company reports that this early start is supporting record production, sales, and earnings in 2025 in what it describes as a challenging market. Warrior Met Coal has also finalized two federal coal leases that add major coal reserves to its asset base. Management highlights these milestones as key drivers for planned production and sales expansion in 2026...
NasdaqGS:DKNG
NasdaqGS:DKNGHospitality

DraftKings (DKNG) Q4 Profitability Upswing Tests Bullish Earnings Narratives

DraftKings (DKNG) closed out FY 2025 with Q4 revenue of US$1.99b and basic EPS of US$0.28, while trailing twelve month EPS edged into positive territory at US$0.01 on revenue of US$6.05b. This helped set the tone for a results season where profitability is firmly in focus. The company has seen quarterly revenue move from US$1.39b in Q4 2024 to US$1.99b in Q4 2025, with basic EPS shifting from a loss of US$0.28 per share to earnings of US$0.28 per share over the same period. This puts the...
NasdaqGS:CRSR
NasdaqGS:CRSRTech

Corsair Gaming (CRSR) Is Up 31.3% After First-Ever US$50 Million Buyback And Profitable Q4

Corsair Gaming, Inc. reported its fourth-quarter and full-year 2025 results on 12 February 2026, with Q4 sales of US$436.86 million and net income of US$25.79 million, alongside its first-ever US$50 million share repurchase authorization. While full-year 2025 still showed a net loss of US$16.16 million, the sharp improvement from the prior year and initiation of buybacks highlight a focus on profitability and capital returns. Next, we'll examine how Corsair's strong Q4 profitability and...
NasdaqGS:CACC
NasdaqGS:CACCConsumer Finance

Credit Acceptance (CACC) Margin Strength Challenges Bearish Credit Risk Narratives

Credit Acceptance (CACC) just closed out FY 2025 with fourth quarter revenue of US$336.5 million and basic EPS of US$11.18, backed by trailing twelve month revenue of about US$1.2 billion and EPS of US$37.02. The company has seen quarterly revenue move from US$254.4 million in Q3 FY 2024 to US$336.5 million in Q4 FY 2025, while basic EPS stepped from US$6.42 to US$11.18 over the same stretch, framing a story in which improving profitability and a 34.2% trailing net margin shape how investors...